- Based on FDA guidance, Anavex Life Sciences (NASDAQ:AVXL) moves ahead with plans to conduct a Phase 2/3 clinical trial assessing ANAVEX 2-73 for the treatment of Alzheimer's disease.
- According to the company, the pharmacokinetics/pharmacodynamics modeling completed in an earlier Phase 2a study will enable it to design the new Phase 2 in such a way as to minimize the risk of failure of the Phase 3. No word, though, on when the trial will commence.
- Shares are up 27% premarket on robust volume.
- Previously: Anavex 2-73 shows positive results in mid-stage Alzheimer's study; shares up 10% premarket (Nov. 9)
Anavex Life Sci advances Alzheimer's candidate; shares up 27% premarket
Recommended For You
About AVXL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AVXL | - | - |
Anavex Life Sciences Corp. |